Koch, Sven D.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet

Rabies epidemiology and controlSARS-CoV-2 and COVID-19 Research

Cited by 530

Cytomegalovirus Infection: A Driving Force in Human T Cell Immunosenescence

KOCH, S., LARBI, A., ÖZCELIK, D., SOLANA, R., GOUTTEFANGEAS, C., ATTIG, S., WIKBY, A., STRINDHALL, J., FRANCESCHI, C., & PAWELEC, G. (2007) · Annals of the New York Academy of Sciences

Cytomegalovirus and herpesvirus researchHerpesvirus Infections and Treatments

Cited by 242

A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 223

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Sebastian, M., Schröder, A., Scheel, B., Hong, H. S., Muth, A., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 209

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

Doener, F., Hong, H. S., Meyer, I., Tadjalli-Mehr, K., Daehling, A., Heidenreich, R., Koch, S. D., Fotin-Mleczek, M., & Gnad-Vogt, U. (2019) · Vaccine

Rabies epidemiology and controlImmunotherapy and Immune Responses

Cited by 48

Messenger RNA vaccination and B-cell responses in NSCLC patients.

Sebastian, M., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., Thomas, M., Schneller, F., Stoehlmacher-Williams, J., Goekkurt, E., et al. (2012) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 13

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

Essink, B. J., Shapiro, C., Isidro, M. G. D., Bradley, P., Pragalos, A., Bloch, M., Santiaguel, J., Frias, M. V., Miyakis, S., Alves de Mesquita, M., et al. (2024) · Human Vaccines & Immunotherapeutics

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 8